Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
India business expects growth improvement with the upcoming launch of Semaglutide (SEMA) in chronic weight management and type 2 diabetes; the company is preparing for a day-one generic launch and has already received regulatory approvals. EBITDA and earnings showed a 13-14% CAGR from FY23 to FY25, indicating strong growth momentum prior to FY26 nine months.
From Sun Pharmaceutical Industries Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business expects growth improvement with the upcoming launch of Semaglutide (SEMA) in chronic weight management and type 2 diabetes; the company is preparing for a day-one generic launch and has already received regulatory approvals.
- Emerging markets showed buoyant growth with 13% constant currency growth, driven by both generics and innovative products, and broad-based growth in key countries like Romania, South Africa, and Brazil.
- Global innovative medicines sales grew 14.3% YoY; specialty business expected to continue doing well, but difficult to comment on quarter-to-quarter basis.
- US business saw marginal growth (0.6%) with some generic sales decline; recovery expected as manufacturing compliance improves enabling new product launches.
- Volume growth in India was strong at 6.3%, outperforming the overall market (IPM at 1.2%).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sun Pharmaceutical Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sun Pharma is investing in building an R&D pipeline for both global generics and innovative medicines.
- Consolidated R&D investment for Q3 FY26 was Rs. 8,928 million (5.8% of sales), with innovative R&D accounting for 30.5% of total R&D spend.
- The company has initiated global Phase-II trials of GL0034 (type-2 diabetes) and filed sBLA for Ilumya with the US FDA.
- Incremental spend of approximately $100 million is planned on new launches like LEQSELVI and UNLOXCYT; this spend will become part of core operating expenses.
- Sun Pharma is evaluating strategic areas such as biosimilars, assessing manufacturing setup, investment requirements, and return timelines before committing.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sun Pharmaceutical Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Sun Pharmaceutical Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹14.6K Cr, net profit ₹2.7K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharma.Inds.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Sun Pharmaceutical Industries Ltd Q3 FY26 results?
India business expects growth improvement with the upcoming launch of Semaglutide (SEMA) in chronic weight management and type 2 diabetes; the company is preparing for a day-one generic launch and has already received regulatory approvals. EBITDA and earnings showed a 13-14% CAGR from FY23 to FY25, indicating strong growth momentum prior to FY26 nine months.
What is Sun Pharmaceutical Industries Ltd share price analysis?
Sun Pharmaceutical Industries Ltd currently shows a neutral. The stock trades at a P/E of 36.7 with a market cap of ₹463,072 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharmaceutical Industries Ltd planning capital expenditure?
Sun Pharma is investing in building an R&D pipeline for both global generics and innovative medicines. - Consolidated R&D investment for Q3 FY26 was Rs.
Keep Sun Pharmaceutical Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.